+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID05701176

Imaging Changes in Activated T-Cell Uptake Using 18FF-AraG PET During Anti-PD-1 Therapy in Advanced Non-Small Cell Lung Cancer

Led by Amsterdam UMC, location VUmc · Updated on 2026-08-18

15

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying changes in the uptake of 18FF-AraG, a tracer that images activated T-cells, in patients with non-small cell lung cancer NSCLC undergoing anti-PD-1 immunotherapy. The goal is to better understand the tumor microenvironment and how it relates to immune cell activity, which may help improve patient selection for immunotherapy. The study focuses on advanced-stage NSCLC patients with specific tumor characteristics and high PD-L1 expression. Participants will undergo three 18FF-AraG PET scans during their anti-PD-1 treatment at the start baseline, at two weeks, and at six weeks. These scans are performed to track the accumulation of activated T-cells in tumor lesions and lymphoid organs over time. The study does not involve additional treatments but monitors changes using this imaging technique. During the study, participants will be monitored through these PET scans and assessments of tumor response to treatment at 12 weeks. Researchers will measure the relative change in tracer uptake and correlate it with tumor response and T-cell activation. Participants will be followed for up to 12 weeks to evaluate these outcomes. Safety and eligibility are carefully assessed, and participants provide informed consent before enrollment.

CONDITIONS

Brief Title

A Clinical Imaging Study of the Changes in [18F]F-AraG Uptake Following Anti-PD-1 Therapy in Non-small Cell Lung Cancer

Research Team

I

Idris Bahce, MD, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here